This is a document preview
AMENDMENT #1 TO THE
The purpose of this amendment (“Amendment”), effective as of the last date signed below (“Effective Date”), is to change certain terms of the above referenced Clinical Trials Agreement (CTA) (“Agreement”). These changes are reflected below and except for these changes, all other provisions remain in full force and effect. Two (2) originals of this amendment are provided for execution; one is to remain with the National Cancer Institute, and the second is to remain with Vion Pharmaceuticals.
The CTA shall be amended to extend the term for conducting clinical studies with this Agent for a period of two (2) years. The date of expiration of this CTA is now January 9, 2008.
“CTIS” means Capital Technology Information Service.
Article 6 is hereby amended as follows:
The contact person for DCTD will be Mr. Charles Hall, Chief,